Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

DNA Markers for Prediabetic Side Effects to Psychotropic Drugs Revealed

  • Genomas published a paper in the January 2 on-line issue of Nature’s Molecular Psychiatry that highlights how understanding a patient's DNA can predict an individual's profile of risk or protection from the antipsychotic drugs prescribed, and thus provide clinicians with better options for drug selection or further preventative treatment.

    Researchers looked at two leading atypical antipsychotic medicines on the market and found that a series of unique DNA variations could predict a patient's likelihood for developing prediabetic side effects such as weight gain. 

    The study, entitled "Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients", was undertaken using Genomas' PhysioGenomics Technology, a platform that analyzes DNA variation within a patient population and compares these differences to physiological characteristics or reactions.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »